S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial

BACKGROUND: The ACTS-CC 02 trial demonstrated that S-1 plus oxaliplatin (SOX) was not superior to tegafur-uracil and leucovorin (UFT/LV) in terms of disease-free survival (DFS) as adjuvant chemotherapy for high-risk stage III colon cancer (any T, N2, or positive nodes around the origin of the feedin...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, J., Sasaki, S., Kusumoto, T., Sakamoto, Y., Yoshida, K., Tomita, N., Maeda, A., Teshima, J., Yokota, M., Tanaka, C., Yamauchi, J., Uetake, H., Itabashi, M., Takahashi, K., Baba, H., Kotake, K., Boku, N., Aiba, K., Morita, S., Takenaka, N., Sugihara, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966838/
https://www.ncbi.nlm.nih.gov/pubmed/33714860
http://dx.doi.org/10.1016/j.esmoop.2021.100077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966838/
https://www.ncbi.nlm.nih.gov/pubmed/33714860
http://dx.doi.org/10.1016/j.esmoop.2021.100077

Ejemplares similares